NCT05753189 - Phase 3 Safety Study for the Treatment of Presbyopia Subjects | Biotech Hunter

Enrollment

362

Participants

Timeline

Start Date

February 21, 2023

Primary Completion Date

February 9, 2024

Study Completion Date

February 9, 2024

Conditions

PresbyopiaNear VisionMiosisEye Diseases

Interventions

DRUG

Aceclidine+Brimonidine combination ophthalmic solution

Combination ophthalmic solution of Aceclidine and Brimonidine

DRUG

Placebo

Placebo: Proprietary Vehicle Solution

DRUG

Aceclidine Ophthalmic Solution

Aceclidine

Trial Locations (36)

16066

Site #312, Cranberry Township

32256

Site #319, Crystal River

32757

Site #309, Mt. Dora

33309

Site #327, San Antonio

36301

Site #326, Dothan

37167

Site #311, Smyrna

38104

Site #315, Memphis

40206

Site #324, Louisville

43065

Site #323, Powell

45242

Site #329, Cincinnati

56308

Site #336, Alexandria

58078

Site #332, West Fargo

58103

Site #310, Fargo

59718

Site #335, Bozeman

61201

Site #317, Rock Island

64154

Site #330, Kansas City

66210

Site #301, Overland Park

66762

Site #307, Pittsburg

78229

Site #318, San Antonio

79902

Site #314, El Paso

80120

Site #308, Littleton

85032

Site #321, Phoenix

85053

Site #328, Phoenix

85202

Site #320, Mesa

85224

Site #302, Chandler

85260

Site #338, Scottsdale

85351

Site #331, Sun City

91204

Site #313, Glendale

92037

Site #334, La Jolla

92663

Site #322, Newport Beach

92843

Site #303, Garden Grove

93105

Site #304, Santa Barbara

94954

Site #306, Petaluma

95670

Site #337, Rancho Cordova

97401

Site #333, Eugene

06810

Site #316, Danbury